{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-049499","form_type":"8-K","ticker":"VTVT","cik":"0001641489","company_name":"vTv Therapeutics Inc.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.946765+00:00","generated_at":"2026-06-05T08:58:17.689440+00:00","sec_items":["1.01","2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"vTv Therapeutics enters $50M ATM with TD Cowen; reports preliminary cash of $9.4M","bullets":["Entered Sales Agreement with TD Cowen for at-the-market offering of up to $50M of Class A common stock at 3% commission.","Preliminary cash and cash equivalents ~$9.4M as of Dec 31, 2023, subject to completion of financial closing and audit.","Terminated prior ATM program with Cantor Fitzgerald on Feb 26, 2024.","Company is not obligated to sell any shares; offering is under existing effective S-3 shelf registration."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-049499","json":"https://secwatch.observer/filing/0001193125-24-049499.json","markdown":"https://secwatch.observer/filing/0001193125-24-049499.md","text":"https://secwatch.observer/filing/0001193125-24-049499.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641489/000119312524049499/0001193125-24-049499-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641489/000119312524049499/d766950d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T08:58:17.689440+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3d460df38161810dde161875b5ef001806d0d909","claim":"vTv Therapeutics Inc. reported preliminary financial results for fiscal year ended December 31, 2023.","evidence_excerpt":"Preliminary Financial Results - Cash Balance as of December 31, 2023 Based upon preliminary estimates and information available to the Company, it expects to report that it had cash and cash equivalents of approximately $9.4 million as of December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641489/000119312524049499/0001193125-24-049499-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended December 31, 2023"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"447d19f870b230a973492bdd66c53abc2411522d","claim":"vTv Therapeutics Inc. entered into Sales Agreement with Cowen and Company, LLC valued at up to $50.0 million (effective 2024-02-28).","evidence_excerpt":"On February 28, 2024, vTv Therapeutics Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement”) with Cowen and Company, LLC (“TD Cowen”), pursuant to which the Company may offer and sell, from time to time, through TD Cowen, as sales agent, shares of the Company’s Class A common stock, par value $0.01 per share, having an aggregate offering price of up to $50.0 million (the “ATM Offering”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641489/000119312524049499/0001193125-24-049499-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Cowen and Company, LLC"},{"label":"Value","value":"up to $50.0 million"},{"label":"Effective","value":"2024-02-28"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}